|
End-of-day quote
Palestine Exchange
2026-09-02
|
5-day change | 1st Jan Change | ||
| 3.550 USD | -1.11% |
|
0.00% | +54.35% |
| 08-13 | Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-30 | Jerusalem Pharmaceuticals Announces Board Changes | CI |
| Market Cap | 128M 110M 103M 94.36M 176M 12.09B 177M 1.23B 474M 6.19B 480M 469M 19.72B | P/E 2024 |
13.7x | P/E 2025 | 8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 117M 101M 94.56M 86.32M 161M 11.06B 162M 1.12B 433M 5.66B 439M 429M 18.03B | EV / Sales 2024 |
1.47x | EV / Sales 2025 | 1.47x |
| Free-Float |
35.74% | Yield 2024 |
2.09% | Yield 2025 | 3.26% |
| 1 day | -1.11% | ||
| 1 month | -0.56% | ||
| 3 months | -4.05% | ||
| 6 months | +52.69% | ||
| Current year | +54.35% |
| 1 week | 3.55 | 3.59 | |
| 1 month | 3.5 | 3.66 | |
| Current year | 2.28 | 4 | |
| 1 year | 1.9 | 4 | |
| 3 years | 1.74 | 4 | |
| 5 years | 1.32 | 4 | |
| 10 years | 0.8 | 4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2013-06-30 | |
Mohammed Natour
DFI | Director of Finance/CFO | - | 2020-02-29 |
Lina Masrouji
CTO | Chief Tech/Sci/R&D Officer | - | 1988-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 91 | - | |
Nidal Kamal
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.11% | 0.00% | +71.08% | +86.35% | 128M | ||
| -0.21% | -1.30% | +18.91% | +65.89% | 48.26B | ||
| -2.49% | -3.62% | +42.16% | +110.97% | 40.5B | ||
| +0.72% | -2.00% | -10.20% | +11.00% | 11.85B | ||
| +3.29% | -2.86% | +14.11% | +81.79% | 11.83B | ||
| -1.50% | -1.50% | +24.76% | +142.59% | 9.36B | ||
| -0.86% | -3.20% | +22.45% | +38.38% | 7.5B | ||
| -1.23% | -1.57% | +39.31% | -13.47% | 7.37B | ||
| +0.60% | -2.51% | +19.49% | +209.21% | 7.28B | ||
| -0.32% | -2.67% | -46.31% | +18.10% | 5.19B | ||
| Average | -0.31% | -2.06% | +19.58% | +75.08% | 14.93B | |
| Weighted average by Cap. | -0.61% | -1.84% | +21.89% | +79.88% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 39.82M 34.25M 32.21M 29.4M 54.99M 3.77B 55.17M 382M 148M 1.93B 150M 146M 6.14B | 48.95M 42.09M 39.59M 36.14M 67.59M 4.63B 67.81M 469M 181M 2.37B 184M 180M 7.55B |
| Net income | 5.04M 4.33M 4.07M 3.72M 6.96M 476M 6.98M 48.32M 18.68M 244M 18.92M 18.51M 777M | 10.18M 8.76M 8.24M 7.52M 14.06M 963M 14.11M 97.66M 37.75M 493M 38.24M 37.41M 1.57B |
| Net Debt | -10.32M -8.88M -8.35M -7.62M -14.25M -976M -14.3M -98.99M -38.26M -500M -38.76M -37.92M -1.59B | -10.9M -9.37M -8.81M -8.05M -15.05M -1.03B -15.1M -105M -40.4M -528M -40.92M -40.03M -1.68B |
Employees
595
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-02 | US$3.550 | -1.11% | 900 |
| 26-09-01 | US$3.590 | +1.13% | 100 |
| 26-08-31 | US$3.550 | 0.00% | 100 |
- Stock Market
- Stocks
- JPH Stock
Select your edition
All financial news and data tailored to specific country editions
















